Status:
COMPLETED
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Glaucoma
Eligibility:
All Genders
36-18 years
Phase:
PHASE3
Brief Summary
To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glau...
Eligibility Criteria
Inclusion
- Male or female of 18 years of age or under
- Diagnosis of glaucoma
- IOP of 22 mmHg or above in at least 1 eye
Exclusion
- Require surgery for acute angle closure
- Have had prior cyclodestructive procedures
- Have a history of ocular trauma or surgery in either eye within 3 months of the baseline visit
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT00716859
Start Date
July 1 2008
End Date
November 1 2009
Last Update
February 3 2021
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Pembroke Pines, Florida, United States, 33028
2
Pfizer Investigational Site
Atlanta, Georgia, United States, 30322
3
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46202
4
Pfizer Investigational Site
Minneapolis, Minnesota, United States, 55455